Physician profile
Christopher M Meyer
NPI 1740411990
$9,645.07
in general payments reported to CMS, 2019-2025
54 companies · $1,556 in 2025
The $1,556 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $775 · 2020: $950 · 2021: $1,650 · 2022: $1,627 · 2023: $1,569 · 2024: $1,518 · 2025: $1,556.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,634 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,634.37 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,459.10 | 2019-2025 | |
| Lilly USA, LLC | $787.39 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $741.38 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Astellas Pharma US INC | $722.50 | 2019-2025 | Veozah, Myrbetriq |
| Astrazeneca Pharmaceuticals Lp | $704.76 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $683.03 | 2019-2025 | Evenity, Otezla, Repatha |
| Glaxosmithkline, LLC. | $437.75 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $424.68 | 2019-2025 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $268.00 | 2019-2025 | Xarelto, Spravato |
| Abbott Laboratories | $234.08 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Bayer Healthcare Pharmaceuticals INC. | $232.21 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $204.99 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $204.73 | 2019-2025 | Jardiance |
| Allergan, INC. | $197.72 | 2019-2020 | |
| Zyla Life Sciences, INC. | $163.43 | 2019 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.